Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Israeli Prime Minister: The Israel Defense Forces are free to operate in southern Lebanon to counter threats.
2026-06-22
Israeli Prime Minister: The Israel Defense Forces are free to operate in southern Lebanon to counter threats.
Back
Other News
2026-06-22
CITIC Securities forecasts robust semiconductor-equipment demand driven by large downstream customers’ capex guidance and expansion plans. It projects the global wafer fab equipment (WFE) market will expand 26% YoY in 2026 to $147.8bn and 35% YoY in
CITIC Securities forecasts robust semiconductor-equipment demand driven by large downstream customers’ capex guidance and expansion plans. It projects the global wafer fab equipment (WFE) market will expand 26% YoY in 2026 to $147.8bn and 35% YoY in 2027 to $199.5bn, with memory’s share increasing. As capacity is brought online and new product cycles roll out, equipment makers’ pricing power may improve. The report advises monitoring equipment suppliers exposed to memory and capex-led spending.
2026-06-22
China's National Medical Products Administration granted priority-review approval to Kaixing Life Sciences (Shanghai) Co. for Shurui Jiaolunsai injection, marketed as Kailimei, for CLDN18.2‑positive, HER2‑negative advanced gastric or gastroesophageal
China's National Medical Products Administration granted priority-review approval to Kaixing Life Sciences (Shanghai) Co. for Shurui Jiaolunsai injection, marketed as Kailimei, for CLDN18.2‑positive, HER2‑negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have progressed after at least two prior lines of therapy. The approval adds a new later‑line treatment option for this biomarker‑defined patient population.
Chat with us
, powered by
LiveChat